Literature DB >> 23519153

The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.

Beom Hee Lee1, Joo Hyun Kim, Jae-Min Kim, Sun Hee Heo, Minji Kang, Gu-Hwan Kim, Jin-Ho Choi, Han-Wook Yoo.   

Abstract

The Long-Evans Cinnamon (LEC) rat shows age-dependent hepatic manifestations that are similar to those of Wilson's disease (WD). The pathogenic process in the brain has, however, not been evaluated in detail due to the rarity of the neurological symptoms. However, copper accumulation is noted in LEC rat brain tissue from 24 weeks of age, which results in oxidative injuries. The current study investigated the gene expression profiles of LEC rat brains at 24 weeks of age in order to identify the important early molecular changes that underlie the development of neurological symptoms in WD. Biological ontology-based analysis revealed diverse altered expressions of the genes related to copper accumulation. Of particular interest, we found altered expression of genes connected to mitochondrial respiration (Sdhaf2 and Ndufb7), calcineurin-mediated cellular processes (Ppp3ca, Ppp3cb, and Camk2a), amyloid precursor protein (Anks1b and A2m) and alpha-synuclein (Snca). In addition to copper-related changes, compensatory upregulations of Cp and Hamp reflect iron-mediated neurotoxicity. Of note, reciprocal expression of Asmt and Bhmt is an important clue that altered S-adenosylhomocysteine metabolism underlies brain injury in WD, which is directly correlated to the decreased expression of S-adenosylhomocysteine hydrolase in hepatic tissue in LEC rats. In conclusion, our study indicates that diverse molecular changes, both variable and complex, underlie the development of neurological manifestations in WD. Copper-related injuries were found to be the principal pathogenic process, but Fe- or adenosylhomocysteine-related injuries were also implicated. Investigations using other animal models or accessible human samples will be required to confirm our observations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519153     DOI: 10.1039/c3mt20243g

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  4 in total

Review 1.  Animal models of Wilson disease.

Authors:  Emily Reed; Svetlana Lutsenko; Oliver Bandmann
Journal:  J Neurochem       Date:  2018-06-26       Impact factor: 5.372

2.  CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson's disease.

Authors:  Rui Wei; Jiayin Yang; Chi-Wa Cheng; Wai-In Ho; Na Li; Yang Hu; Xueyu Hong; Jian Fu; Bo Yang; Yuqing Liu; Lixiang Jiang; Wing-Hon Lai; Ka-Wing Au; Wai-Ling Tsang; Yiu-Lam Tse; Kwong-Man Ng; Miguel A Esteban; Hung-Fat Tse
Journal:  JHEP Rep       Date:  2021-10-30

3.  System Pharmacology-Based Strategy to Decode the Synergistic Mechanism of GanDouLing for Wilson's Disease.

Authors:  Juan Zhang; Hong Chen; Yuancheng Bao; Daojun Xie; Wenming Yang; Huaizhou Jiang; Ting Dong; Hui Han
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-29       Impact factor: 2.629

4.  Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases.

Authors:  Hai-Biao Yan; Yu Zhang; Jie-Mei Cen; Xiao Wang; Bin-Liang Gan; Jia-Cheng Huang; Jia-Yi Li; Qian-Hui Song; Sheng-Hua Li; Gang Chen
Journal:  Med Sci Monit       Date:  2018-07-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.